Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.45 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.40 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | MBTPS1 | Q14703 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13003423 | 0.87 | CCR1 (0.47) | CCR1DRD2DRD3OPRM1OPRD1 | |
| SCHEMBL13003426 | 0.83 | CYP3A4 (0.52) | NPSR1TEAD1 | |
| SCHEMBL13588404 | 0.78 | EPHX1 (0.59) | SMYD3EPHX2 | |
| SCHEMBL3324997 | 0.72 | PTGES (0.45) | DRD2NPSR1TSHR | |
| SCHEMBL3325000 | 0.72 | PTGES (0.45) | DRD2NPSR1TSHR | |
| SCHEMBL3325364 | 0.72 | PTGES (0.45) | DRD2NPSR1TSHR | |
| SCHEMBL6011947 | 0.69 | MAOB (0.50) | NPSR1CNR1 | |
| SCHEMBL13391197 | 0.68 | MGLL (0.65) | — | |
| SCHEMBL20766350 | 0.67 | HTR2A (0.51) | MBTPS1HTR2A | |
| SCHEMBL14306242 | 0.67 | CCR1 (0.74) | CCR1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846946-B2 | Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists | SCHERING PLOUGH CORPORATION (US) | 2010-12-07 | — | — | US | disclosed |
| US-7635705-B2 | treating allergy-induced airway responses, congestion, obesity, metabolic syndrome, alcoholic fatty liver disease, hepatic steatosis, nonalcoholic steatohepatitis, cirrhosis, hepatacellular carcinoma and cognition deficit disorders; histamine H3 antagonists | SCHERING CORPORATION (US) | 2009-12-22 | — | — | US | disclosed |
| US-20090286830-A1 | HETEROATOM-LINKED SUBSTITUTED PIPERIDINES AND DERIVATIVES THEREOF USEFUL AS HISTAMINE H3 ANTAGONISTS | SCHERING CORPORATION | 2009-11-19 | — | — | US | disclosed |
| US-20070015807-A1 | Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists | SCHERING CORPORATION | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015807-A1 | Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists | HRH3, HRH4, CHRM2 | CCR1 132/4885SMYD3 968/4885DRD2 367/4885 |
| US-20090286830-A1 | HETEROATOM-LINKED SUBSTITUTED PIPERIDINES AND DERIVATIVES THEREOF USEFUL AS HISTAMINE H3 ANTAGONISTS | HRH3, HRH4, CHRM2 | CCR1 132/4885SMYD3 968/4885DRD2 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.